adenocarcinoma (Cancer)
Information
- Disease name
- adenocarcinoma
- Disease ID
- DOID:299
- Description
- "A carcinoma that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue." [url:http\://en.wikipedia.org/wiki/Adenocarcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02905578 | Active, not recruiting | Phase 2 | A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) | November 28, 2018 | December 31, 2025 |
| NCT05511116 | Active, not recruiting | Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI | July 18, 2022 | December 31, 2023 | |
| NCT05241873 | Active, not recruiting | Phase 1/Phase 2 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | March 4, 2022 | July 25, 2026 |
| NCT02795988 | Active, not recruiting | Phase 1/Phase 2 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | August 30, 2017 | August 2024 |
| NCT04222972 | Active, not recruiting | Phase 3 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | July 24, 2020 | June 30, 2025 |
| NCT02664935 | Active, not recruiting | Phase 2 | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | May 2015 | September 2024 |
| NCT04862780 | Active, not recruiting | Phase 1/Phase 2 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | June 29, 2021 | January 31, 2025 |
| NCT04660929 | Active, not recruiting | Phase 1 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | February 2, 2021 | December 31, 2024 |
| NCT01946100 | Active, not recruiting | N/A | Treatment of Multifocal Lung Adenocarcinoma | October 2013 | October 2025 |
| NCT04400474 | Active, not recruiting | Phase 2 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | October 7, 2020 | March 2024 |
| NCT01393483 | Active, not recruiting | Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) | March 2011 | September 2024 | |
| NCT00911118 | Active, not recruiting | Phase 1 | Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer | May 2009 | May 2025 |
| NCT03488667 | Active, not recruiting | Phase 2 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | June 27, 2018 | April 30, 2025 |
| NCT00201838 | Completed | Phase 1/Phase 2 | Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | July 2001 | May 2007 |
| NCT00230347 | Completed | Phase 1 | Evaluation of Stereotactic Radiosurgery For Liver Malignancies | October 2003 | February 2007 |
| NCT00259987 | Completed | Phase 2 | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus | November 2005 | May 2007 |
| NCT00298545 | Completed | Phase 1 | Effect of Vitamin D and Calcium on Genes in the Colon | November 2005 | May 2009 |
| NCT00321048 | Completed | N/A | Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC | June 2006 | January 2010 |
| NCT00377936 | Completed | Phase 2 | EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas | September 2005 | October 2008 |
| NCT00395252 | Completed | Phase 2 | Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer | October 2006 | January 2012 |
| NCT00430261 | Completed | Phase 2 | Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma | January 2007 | October 2010 |
| NCT00436657 | Completed | Phase 1 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | February 2007 | April 2011 |
| NCT00443196 | Completed | Phase 2/Phase 3 | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | March 2006 | September 2010 |
| NCT00495924 | Completed | Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma | October 2006 | October 2008 | |
| NCT00507091 | Completed | Phase 1 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | August 2005 | June 2008 |
| NCT00548548 | Completed | Phase 3 | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer | September 2007 | November 2013 |
| NCT00600821 | Completed | Phase 2 | A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. | April 2008 | October 2012 |
| NCT00661830 | Completed | Phase 2 | Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) | May 2008 | June 2010 |
| NCT00688753 | Completed | Phase 2 | RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe | July 2009 | October 2014 |
| NCT00719264 | Completed | Phase 2 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | November 12, 2008 | April 15, 2013 |
| NCT00795184 | Completed | N/A | Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy | November 2008 | February 2010 |
| NCT00895349 | Completed | N/A | Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial) | April 2010 | August 2019 |
| NCT00917384 | Completed | Phase 3 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | August 2009 | December 2015 |
| NCT00054873 | Completed | Phase 2 | Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer | November 2003 | December 2004 |
| NCT00083278 | Completed | Phase 2 | Study of MDX-010 in Stage IV Breast Cancer | May 2003 | February 2006 |
| NCT00088413 | Completed | Phase 1/Phase 2 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | July 21, 2004 | May 31, 2018 |
| NCT00094445 | Completed | Phase 2 | Trial of Curcumin in Advanced Pancreatic Cancer | November 2004 | April 2014 |
| NCT00102700 | Completed | Phase 2 | ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer | January 2005 | January 2007 |
| NCT00106353 | Completed | Phase 1/Phase 2 | Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors | March 2005 | January 2012 |
| NCT00127478 | Completed | Phase 2/Phase 3 | A Long Term Safety Study With Atrasentan | July 2001 | June 2007 |
| NCT00129844 | Completed | Phase 2 | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer | September 2005 | December 2007 |
| NCT00137839 | Completed | Phase 2 | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | November 2004 | July 2019 |
| NCT00140075 | Completed | Phase 3 | Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer | November 2000 | August 2006 |
| NCT00183859 | Completed | Phase 1 | Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan | September 1999 | April 2009 |
| NCT00191503 | Completed | Phase 2 | Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma | January 2005 | November 2005 |
| NCT00051675 | Completed | Phase 1 | Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas | July 2002 | September 2003 |
| NCT00918853 | Completed | N/A | Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas | August 2008 | May 2012 |
| NCT00940069 | Completed | Phase 2 | TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer | March 2009 | January 2015 |
| NCT00949650 | Completed | Phase 3 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | August 14, 2009 | March 16, 2017 |
| NCT01020630 | Completed | Phase 2 | Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI | November 2009 | July 2013 |
| NCT01032044 | Completed | N/A | CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia | February 2010 | April 2011 |
| NCT01051934 | Completed | Phase 1 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | December 29, 2009 | September 28, 2011 |
| NCT01077817 | Completed | Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352) | February 26, 2010 | February 16, 2012 | |
| NCT01077999 | Completed | Phase 2 | Chemoradiation and Panitumumab for Esophageal Cancer | January 2010 | April 2012 |
| NCT01121393 | Completed | Phase 3 | BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) | April 19, 2010 | November 26, 2017 |
| NCT01135823 | Completed | Symptom Assessment With Patient Surveys | July 2006 | June 2008 | |
| NCT01161186 | Completed | Phase 1 | Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma | July 2010 | October 2012 |
| NCT01206530 | Completed | Phase 1/Phase 2 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | September 2010 | September 2017 |
| NCT01249352 | Completed | Phase 2/Phase 3 | A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer | January 2009 | November 2013 |
| NCT01253525 | Completed | Phase 1 | Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas | November 2010 | October 2011 |
| NCT01295086 | Completed | N/A | Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer | March 2011 | January 2018 |
| NCT01365156 | Completed | Phase 3 | Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix | August 2011 | January 24, 2020 |
| NCT01383538 | Completed | Phase 1 | FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | August 23, 2011 | May 26, 2015 |
| NCT01433172 | Completed | Phase 1/Phase 2 | Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer | March 26, 2012 | February 1, 2019 |
| NCT01519817 | Completed | Phase 1 | Cancer Vaccine Targeting Brachyury Protein in Tumors | January 5, 2012 | September 1, 2016 |
| NCT01579721 | Completed | Phase 4 | Prospective Randomized Study of SILS Versus CLS for Rectal Cancer | September 2011 | October 2012 |
| NCT01646697 | Completed | N/A | Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery | November 7, 2011 | February 6, 2016 |
| NCT01677559 | Completed | Phase 1 | Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies | May 7, 2013 | August 11, 2017 |
| NCT01761240 | Completed | Phase 1 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | June 19, 2013 | February 9, 2016 |
| NCT01778920 | Completed | Phase 1 | Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA) | April 2012 | May 2016 |
| NCT01824966 | Completed | Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma | March 2012 | December 2012 | |
| NCT01962532 | Completed | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma | August 21, 2013 | January 28, 2016 |
| NCT02082886 | Completed | HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry | February 2014 | January 2020 | |
| NCT02130011 | Completed | N/A | Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose | March 2014 | September 2015 |
| NCT02151149 | Completed | Phase 4 | Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly | June 9, 2014 | July 14, 2017 |
| NCT02183870 | Completed | Phase 2 | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | May 2014 | February 29, 2020 |
| NCT02204046 | Completed | Phase 1 | Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast | January 2000 | |
| NCT02213289 | Completed | Phase 2 | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | January 20, 2015 | August 20, 2020 |
| NCT02335151 | Completed | Phase 4 | CTC Pancreatic Adenocarcinoma | October 2016 | October 2019 |
| NCT02347618 | Completed | N/A | Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer | December 2014 | April 13, 2022 |
| NCT02370303 | Completed | A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System | August 2014 | July 9, 2016 | |
| NCT02374411 | Completed | Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients | September 2014 | March 2015 | |
| NCT02394652 | Completed | Phase 2 | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial | May 21, 2015 | January 12, 2021 |
| NCT02410603 | Completed | Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer | December 2016 | January 1, 2021 | |
| NCT02426879 | Completed | N/A | Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases | February 11, 2015 | January 25, 2021 |
| NCT02428270 | Completed | Phase 2 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | April 2016 | October 27, 2022 |
| NCT02454647 | Completed | Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients | September 2013 | March 2015 | |
| NCT02498860 | Completed | Phase 2 | Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung | September 1, 2015 | July 31, 2021 |
| NCT02653248 | Completed | Phase 1 | SBRT for Organ Confined Prostate Cancer | August 2010 | December 2021 |
| NCT02875340 | Completed | Phase 2 | A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | October 2016 | September 2017 |
| NCT02926768 | Completed | Phase 1 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | September 2016 | June 2022 |
| NCT03037385 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | March 17, 2017 | March 21, 2024 |
| NCT03415854 | Completed | Phase 2 | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) | January 31, 2018 | December 11, 2023 |
| NCT03462524 | Completed | Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology | January 1, 2010 | January 1, 2018 | |
| NCT03535727 | Completed | Phase 1/Phase 2 | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | June 21, 2018 | October 3, 2022 |
| NCT03578939 | Completed | Next Generation Sequencing of Tumor Cells in Locally Advanced Pancreatic Adenocarcinoma | January 1, 2017 | February 28, 2021 | |
| NCT03695835 | Completed | A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. | April 11, 2018 | June 17, 2020 | |
| NCT04263090 | Completed | Phase 1/Phase 2 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | June 29, 2020 | December 20, 2023 |
| NCT05337163 | Completed | A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China | February 25, 2022 | August 29, 2023 | |
| NCT00923026 | Enrolling by invitation | Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies | June 15, 2009 | ||
| NCT00102544 | Enrolling by invitation | N/A | Use of Tracking Devices to Locate Abnormalities During Invasive Procedures | February 23, 2005 | December 2, 2024 |
| NCT06241469 | Not yet recruiting | Phase 2 | Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study | February 3, 2024 | February 2, 2027 |
| NCT06090214 | Not yet recruiting | N/A | Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE) | December 1, 2023 | December 1, 2025 |
| NCT06358001 | Not yet recruiting | EchoTip AcuCore Post-Market Clinical Study | June 1, 2024 | June 1, 2025 | |
| NCT05574647 | Not yet recruiting | N/A | Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer | October 1, 2022 | January 31, 2026 |
| NCT04361708 | Recruiting | Phase 1 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | May 8, 2020 | May 2027 |
| NCT02973828 | Recruiting | PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy | October 17, 2017 | December 31, 2024 | |
| NCT04543071 | Recruiting | Phase 2 | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | November 9, 2020 | August 2025 |
| NCT06128343 | Recruiting | Anatomical-Clinical Base of Adenocarcinoma Pancreatic | November 16, 2023 | February 28, 2035 | |
| NCT05273554 | Recruiting | Phase 1 | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | August 31, 2022 | January 15, 2025 |
| NCT06121700 | Recruiting | Phase 2 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer | January 1, 2023 | December 31, 2027 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT06046131 | Recruiting | N/A | Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. | February 28, 2023 | February 28, 2039 |
| NCT04401059 | Recruiting | Phase 4 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study | November 9, 2020 | March 30, 2026 |
| NCT06337760 | Recruiting | YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. | March 10, 2023 | June 30, 2027 | |
| NCT04374175 | Recruiting | SERum-bank for PANcreatic Cancer | April 1, 2020 | January 1, 2026 | |
| NCT06405035 | Recruiting | Dissecting the Role of MIcrobioMe in gastroEsophageal Tumor: a multIdisCiplinary Longitudinal Study | March 8, 2022 | March 8, 2026 | |
| NCT05922930 | Recruiting | Phase 1/Phase 2 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | October 11, 2023 | July 1, 2028 |
| NCT02133196 | Recruiting | Phase 2 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | October 23, 2014 | October 23, 2025 |
| NCT05581121 | Recruiting | Phase 3 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer | December 20, 2023 | December 2033 |
| NCT04644770 | Recruiting | Phase 1 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | November 12, 2020 | December 26, 2025 |
| NCT05065736 | Recruiting | Early Phase 1 | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer | March 6, 2023 | December 5, 2024 |
| NCT05678218 | Recruiting | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma | September 5, 2022 | February 1, 2026 | |
| NCT05892926 | Recruiting | HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia | May 30, 2023 | July 1, 2024 | |
| NCT02292641 | Recruiting | N/A | Beyond TME Origins | September 25, 2014 | December 2029 |
| NCT04069273 | Recruiting | Phase 2 | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma | December 1, 2020 | December 10, 2025 |
| NCT05161572 | Recruiting | Phase 2 | Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer | September 28, 2021 | September 30, 2026 |
| NCT05935748 | Recruiting | Phase 2 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | July 28, 2023 | September 2026 |
| NCT01125449 | Suspended | Phase 2 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | January 2011 | December 2014 |
| NCT01476553 | Terminated | N/A | Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in Patients With Gastric Cancer | February 2011 | March 2013 |
| NCT00127036 | Terminated | Phase 2 | Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | October 2003 | December 2010 |
| NCT05153408 | Terminated | Phase 1 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | January 13, 2022 | December 9, 2022 |
| NCT00116389 | Terminated | Phase 2 | Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas | ||
| NCT02387216 | Terminated | Phase 2 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | February 1, 2015 | January 2, 2019 |
| NCT02404506 | Terminated | Phase 2 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | August 17, 2015 | July 22, 2021 |
| NCT02473094 | Terminated | Phase 2 | Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer | July 2015 | February 2016 |
| NCT02487277 | Terminated | Phase 2 | PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | July 14, 2015 | May 18, 2018 |
| NCT00672009 | Terminated | Phase 2 | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | April 2008 | August 2012 |
| NCT00632203 | Terminated | Phase 2 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | March 4, 2008 | January 7, 2011 |
| NCT00892242 | Terminated | Phase 1 | Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer | December 2009 | April 2013 |
| NCT00507702 | Terminated | Identification of Key Blood Molecular Markers for Immunotherapy | July 6, 2006 | February 25, 2015 | |
| NCT01009593 | Terminated | Phase 3 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | January 2010 | July 2012 |
| NCT03000179 | Terminated | Phase 2 | Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma | March 3, 2017 | August 3, 2021 |
| NCT00368329 | Terminated | Phase 1 | Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer | June 2006 | March 2009 |
| NCT01363466 | Terminated | Phase 3 | Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer | May 2003 | November 2006 |
| NCT01365143 | Terminated | Phase 4 | Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy | May 2011 | February 2014 |
| NCT03840967 | Terminated | Phase 2 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | July 9, 2019 | February 22, 2023 |
| NCT03997448 | Terminated | Phase 2 | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | August 26, 2019 | January 30, 2020 |
| NCT01441128 | Terminated | Phase 1 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | September 1, 2011 | February 26, 2015 |
| NCT01784861 | Terminated | Phase 1/Phase 2 | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | May 3, 2013 | August 19, 2020 |
| NCT00201734 | Terminated | Phase 1/Phase 2 | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary | June 2005 | June 2013 |
| NCT01182246 | Unknown status | Phase 1/Phase 2 | AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer | November 2010 | March 2016 |
| NCT02795650 | Unknown status | Phase 2 | Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation | May 2016 | September 2022 |
| NCT03591666 | Unknown status | Phase 2 | A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas | July 15, 2018 | December 31, 2020 |
| NCT03636685 | Unknown status | Phase 1/Phase 2 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | August 15, 2018 | August 14, 2020 |
| NCT02788669 | Unknown status | LRP1 and Colon Cancer | November 2015 | May 2017 | |
| NCT00201331 | Unknown status | Phase 2 | Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer | April 2002 | October 2012 |
| NCT02103257 | Unknown status | Phase 4 | Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma | March 2014 | September 2017 |
| NCT03013010 | Unknown status | Phase 3 | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy | December 2016 | December 2023 |
| NCT01037049 | Unknown status | Phase 2 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | October 16, 2009 | December 8, 2019 |
| NCT02980536 | Unknown status | cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | November 2016 | December 2018 | |
| NCT01130233 | Unknown status | Phase 3 | Randomized Trial on Robotic Assisted Resection for Rectal Cancer | June 2009 | December 2014 |
| NCT01930864 | Unknown status | Phase 2 | Metformin Plus Irinotecan for Refractory Colorectal Cancer | September 1, 2015 | December 1, 2020 |
| NCT01171300 | Unknown status | N/A | Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients | October 2010 | December 2016 |
| NCT00751543 | Unknown status | N/A | The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy | January 2008 | |
| NCT01952951 | Unknown status | Phase 2 | Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer | June 2014 | December 2019 |
| NCT04667403 | Unknown status | N/A | Telemedicine in the Management of Pain in Patients With Advanced or Metastatic Pancreatic Cancer | February 7, 2022 | February 8, 2024 |
| NCT01995942 | Unknown status | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | June 7, 2013 | February 2, 2022 | |
| NCT02785757 | Unknown status | N/A | Cancer-related Thromboembolic Disease | July 12, 2014 | February 12, 2024 |
| NCT02005965 | Unknown status | Low Rectal Cancer Study (MERCURY II) | August 13, 2007 | March 11, 2021 | |
| NCT02125240 | Unknown status | Phase 3 | Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma | September 2014 | July 2021 |
| NCT01502202 | Unknown status | Phase 2 | Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers | March 2012 | February 2015 |
| NCT02741778 | Unknown status | N/A | Minimally Invasive Sweet Esophagectomy for Patients With Siewert Type II Adenocarcinoma of the Esophagogastric Junction | January 2015 | December 2017 |
| NCT01556815 | Unknown status | Phase 2 | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma | May 2012 | May 2015 |
| NCT04227886 | Unknown status | Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer | December 1, 2019 | December 31, 2021 | |
| NCT01665417 | Unknown status | Phase 4 | Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma | August 2012 | December 2017 |
| NCT02194556 | Unknown status | Phase 4 | Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC | July 2014 | July 2017 |
| NCT01301612 | Withdrawn | Phase 2 | Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS) | January 2011 | |
| NCT01148082 | Withdrawn | School Response to Families Who Have Children With Cancer | September 2010 | July 2011 | |
| NCT02943603 | Withdrawn | Phase 2 | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | January 2017 | July 2019 |
| NCT05325164 | Withdrawn | Phase 3 | Methadone for 'Adenocarcinopathic' Pain Treatment | September 2022 | September 2023 |
| NCT02341170 | Withdrawn | N/A | HS-PCI in Locally Advanced Adenocarcinoma of the Lung | January 2016 | March 2019 |
| NCT00800969 | Withdrawn | Phase 2 | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach | October 2008 | |
| NCT00247936 | Withdrawn | N/A | Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial. | May 2004 | May 2004 |
| NCT01640847 | Withdrawn | Phase 2 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | July 2012 | July 2013 |
- Disase is a (Disease Ontology)
- DOID:305
- Cross Reference ID (Disease Ontology)
- ICDO:8140/3
- Cross Reference ID (Disease Ontology)
- MESH:D000230
- Cross Reference ID (Disease Ontology)
- NCI:C2852
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:35917007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0001418
- MeSH unique ID (MeSH (Medical Subject Headings))
- D000230